Kenneth Nilsson
Professor emeritus at Department of Immunology, Genetics and Pathology; Research programme: Cancer Precision Medicine; Research group Helena Jernberg Wiklund
- Mobile phone:
- +46 70 832 16 44
- E-mail:
- kenneth-n.nilsson@igp.uu.se
- Visiting address:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postal address:
- Rudbecklaboratoriet
751 85 UPPSALA
Publications
Recent publications
Part of Oncotarget, p. 103731-103743, 2017
- DOI for The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomain
- Download full text (pdf) of The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomain
Part of Oncotarget, p. 10213-10224, 2017
- DOI for EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
- Download full text (pdf) of EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
The Transcriptomic and Proteomic Landscapes of Bone Marrow and Secondary Lymphoid Tissues
Part of PLOS ONE, 2014
- DOI for The Transcriptomic and Proteomic Landscapes of Bone Marrow and Secondary Lymphoid Tissues
- Download full text (pdf) of The Transcriptomic and Proteomic Landscapes of Bone Marrow and Secondary Lymphoid Tissues
Part of Blood, 2014
Part of Leukemia and Lymphoma, p. 1769-1779, 2013
All publications
Articles in journal
Part of Oncotarget, p. 103731-103743, 2017
- DOI for The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomain
- Download full text (pdf) of The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomain
Part of Oncotarget, p. 10213-10224, 2017
- DOI for EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
- Download full text (pdf) of EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
The Transcriptomic and Proteomic Landscapes of Bone Marrow and Secondary Lymphoid Tissues
Part of PLOS ONE, 2014
- DOI for The Transcriptomic and Proteomic Landscapes of Bone Marrow and Secondary Lymphoid Tissues
- Download full text (pdf) of The Transcriptomic and Proteomic Landscapes of Bone Marrow and Secondary Lymphoid Tissues
Part of Blood, 2014
Part of Leukemia and Lymphoma, p. 1769-1779, 2013
Part of BMC Cancer, p. 318, 2012
- DOI for Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma
- Download full text (pdf) of Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma
Tumor-Initiating Cells in Childhood Neuroblastoma: Letter
Part of Cancer Research, p. 821-822, 2012
The novel NF-kappa B inhibitor IMD-0354 induces apoptosis in chronic lymphocytic leukemia
Part of Blood Cancer Journal, 2011
Large-Scale Protein Profiling in Human Cell Lines Using Antibody-Based Proteomics
Part of Journal of Proteome Research, p. 4066-4075, 2011
Polycomb target genes are silenced in multiple myeloma
Part of PLOS ONE, 2010
- DOI for Polycomb target genes are silenced in multiple myeloma
- Download full text (pdf) of Polycomb target genes are silenced in multiple myeloma
Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma
Part of Experimental Hematology, p. 1673-1681, 2008
Positive histone marks are associated with active transcription from a methylated ICSBP/IRF8 gene
Part of Gene, p. 259-267, 2008
Part of Molecular Immunology, p. 615-624, 2007
Part of International Journal of Cancer, p. 1857-1861, 2007
Part of Scandinavian Journal of Immunology, p. 271-279, 2006
Part of Blood, p. 669-78, 2006
Part of Blood, p. 655-60, 2006
Part of Blood, 2005
Part of Leukemia, p. 871-873, 2005
Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone.
Part of Blood, p. 3138-47, 2004
Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines.
Part of Anticancer Drugs, p. 63-70, 2004
Part of Leukemia Res, p. 1043-1051, 2004
Differentiation-associated redox-regulation in human B cell lines from stemcell/pro-B to plasma cell
Part of Immunology Letters, p. 83-89, 2004
VH gene mutation status and cellular drug resistance in chronic lymphocytic leukemia
Part of Eur J Haematol, p. 407-411, 2004
Part of Anti-Cancer Drugs, p. 45-54, 2004
Part of Thrombosis and Haemostasis, p. 930-9, 2003
Part of Int J Cancer, p. 197-201, 2003
Part of Blood, p. 254, 2003
Part of Eur J Haematol, p. 76-89, 2002
Part of Blood, p. 2199, 2002
Part of Leukemia, p. 217-227, 2001
The role of RAR and RXR activation in retinoid-induced tissue factor suppression
Part of Leukemia, p. 1105-11, 2000
Thioredoxin prolongs survival of B-type chronic lymphocytic leukemia cells
Part of Blood, p. 1420-1426, 2000
Part of Biometals, p. 101-11, 2000
Part of Blood, p. 2870, 2000
Part of European Journal of Haematology, p. 112-119, 1999
Part of Scand J Immunol, p. 363-70, 1999
Part of Blood, p. 1724, 1999
Part of Blood, p. 2914, 1998
Part of Journal of Biological Chemistry, p. 9443-9, 1997
- DOI for Retinoic acid receptor/retinoid X receptor heterodimers can be activated through both subunits providing a basis for synergistic transactivation and cellular differentiation
- Download full text (pdf) of Retinoic acid receptor/retinoid X receptor heterodimers can be activated through both subunits providing a basis for synergistic transactivation and cellular differentiation
Part of Leukemia, p. 142-4, 1997
Myeloperoxidase mediates cell adhesion via the alpha M beta 2 integrin (Mac-1, CD11b/CD18)
Part of Journal of Cell Science, p. 1133-1139, 1997
Tissue factor expression in human monocytic cell lines
Part of Thrombosis Research, p. 215-28, 1997
Part of Leukemia, p. 1298-304, 1997
Part of Br J Haematol, p. 126-33, 1997
Part of Br J Haematol, p. 126, 1997
Part of Scand J Immunol, p. 706-14, 1997
Part of Cell growth & differentiation, p. 1239-49, 1996
Characterization of a human basophil-like cell line (LAMA-84)
Part of Scand. J. Immunol., p. 54-61, 1996
Part of Immunology, p. 308-314, 1996
Part of Int. J. Cancer, p. 451, 1996
Insulin-like growth factor I is a growth- and survival factor in human multiple myeloma cell lines.
Part of Blood, p. 2250, 1996
Part of Leukemia, p. 2034-41, 1995
Articles, review/survey
Part of Upsala Journal of Medical Sciences, p. 166-177, 2012
Control of Apoptosis in Human Multiple Myeloma by Insulin-like Growth Factor I (IGF-I)
Part of Advances in Cancer Research, p. 139-165, 2007
Chapters in book
Plasma Cell and Myeloma Cell Lines
Part of Human Cell Culture, Kluwer Academic Publishers, 2000
Stat1 involvement in retinoic acid induced differentiation of myeloid cells
Part of Molecular mechanisms of signal transduction, p. 211, IOS press, Amsterdam, The Netherlands, 2000
Part of Transplantation Biology, p. 241, Lippincott-Raven, 1996
Conference papers
Cytokine induced inhibition of Myc activity in monocytic cells
Part of C-myc in B-cell neoplasia, p. 191, 1997
Manuscripts (preprints)
Other
Toward a rational combinaTORial therapy for multiple myeloma
Part of Blood, p. 3845-3846, 2004
The control of proliferation, survival and apoptosis in human multiple myeloma cells in vitro
Part of MECHANISMS OF B CELL NEOPLASIA 1998, p. 325-333, 1999